Management of imatinib-resistant patients with chronic myeloid leukemia

Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new sec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bhamidipati, Pavan Kumar, Kantarjian, Hagop, Cortes, Jorge, Cornelison, A. Megan, Jabbour, Elias
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2013
Konular:
Reviews
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3629755/
https://ncbi.nlm.nih.gov/pubmed/23610618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620712468289
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller